GlaxoSmithKline
United States
About GlaxoSmithKline
3119 articles with GlaxoSmithKline
-
MHRA Approves XEVUDY® (sotrovimab), GlaxoSmithKline and Vir Biotechnology's Monoclonal Antibody Treatment for Patients with COVID‑19
12/7/2021
Brand Institute is proud to announce its successful partnership with GlaxoSmithKline and Vir Biotechnology in developing the brand name XEVUDY®, a monoclonal antibody therapeutic approved for symptomatic adults and adolescents (12 years of age and older) with acute COVID–19 infection.
-
Despite having 37 new mutations in the viral spike protein, there does not appear to be any deaths associated with Omicron, although it’s spreading rapidly in South Africa.
-
Preclinical Studies Demonstrate Sotrovimab Retains Activity Against the Full Combination of Mutations in the Spike Protein of the Omicron SARS-CoV-2 Variant
12/7/2021
GlaxoSmithKline plc and Vir Biotechnology, Inc. announced an update to preclinical data on bioRxiv1, a preprint server, demonstrating that sotrovimab, an investigational monoclonal antibody, retains in vitro activity against the full known Omicron spike protein, the new SARS-CoV-2 variant.
-
Preclinical Data Demonstrate Sotrovimab Retains Activity Against Key Omicron Mutations, New SARS-CoV-2 Variant
12/2/2021
GlaxoSmithKline plc and Vir Biotechnology, Inc. announced an update to bioRxiv, a preprint server, with preclinical data demonstrating that sotrovimab, an investigational monoclonal antibody, retains activity against key mutations of the new Omicron SARS-CoV-2 variant, including those found in the binding site of sotrovimab.
-
GlaxoSmithKline said early research shows its monoclonal antibody is demonstrating efficacy against the newest strain of COVID-19.
-
GSK unveils Target the Future, a global, multi-year program to help address key challenges affecting the multiple myeloma community
12/1/2021
GlaxoSmithKline plc launched Target the Future, an international, multi-year initiative dedicated to advancing innovation and addressing key needs in the multiple myeloma community.
-
Genoskin’s solution is to develop the technologies to replace animals and humans in clinical studies with virtual models, steadily pushing living creatures further and further from testing.
-
Early tests of Regeneron’s antibody cocktail show it isn’t as effective against Omicron while a separate tests of Eli Lilly’s antibody cocktail also demonstrated the same.
-
It's been a busy week so far, with new discovery facilities launched in the biotech space.
-
ARO-HSD will be evaluated in a Phase I/II trial that will assess the safety, tolerability, pharmacokinetics, and pharmacodynamic effects of its ability to target HSD17B13 as a treatment for NASH.
-
GSK showcases progress from the DREAMM clinical trial program in multiple myeloma at the 2021 ASH Annual Meeting
11/18/2021
GlaxoSmithKline (GSK) plc today announced 11 abstracts on Blenrep will be presented at the upcoming American Society of Hematology (ASH) Annual Meeting and Exposition, to be hosted in Atlanta, Georgia, US and virtually, December 11-14, 2021.
-
Two weeks after Novartis announced it would sell its nearly one-third voting stake in next-door neighbor Roche, investors are chomping at the bit to find out how that almost $21 billion will be put to work.
-
While COVID-19 appears to be surging again in the U.S. and Europe, the government is spending billions to acquire antibody and antiviral therapies and edging toward vaccination boosters.
-
Race is Heating Up for the First RSV Vaccine
11/17/2021
The market is expected to be worth $4.2 billion by 2027, with a CAGR of 14.9% between 2021 and 2027. -
GSK and Vir Biotechnology Announce United States Government Agreements to Purchase Sotrovimab, a COVID-19 Treatment
11/17/2021
GlaxoSmithKline plc and Vir Biotechnology, Inc. today announced US government contracts totaling approximately $1 billion (USD) to purchase sotrovimab.
-
Clinical Catch-Up: November 8-12
11/15/2021
It was another busy week for clinical trial news. Here’s a look. -
Primary endpoint met in COMET-TAIL Phase 3 trial evaluating intramuscular administration of sotrovimab for early treatment of COVID-19
11/12/2021
GlaxoSmithKline plc today announced headline data from the randomized, multi-center, open-label COMET-TAIL Phase 3 trial was non-inferior to intravenous (IV) administration for the early treatment of mild-to-moderate COVID-19 in high-risk, non-hospitalized adults and adolescents (12 years of age and older).
-
A research team at the University of North Carolina – Chapel Hill (UNC) and Duke University, in Durham, NC identified an antibody that attacks SARS-CoV-2 and its variants and other types of coronaviruses.
-
GlaxoSmithKline is lining up a potential new treatment for patients with anemia due to chronic kidney disease following positive results in a Phase III study.
-
Clinical Catch-Up: November 1-5
11/8/2021
The first week of November was marked by numerous clinical trial announcements. Here’s a look.